Evaluation of the safety and efficacy of direct oral anticoagulants compared with vitamin-k antagonists in the treatment of left ventricular thrombosis. A systematic review and meta-analysis
Evaluation of the safety and efficacy of direct oral anticoagulants compared with vitamin-k antagonists in the treatment of left ventricular thrombosis. A systematic review and meta-analysis
Mehrpooya et al., 2024 | Heart Lung | Meta Analysis
Citation
Mehrpooya Maryam, Barakzehi Mohammad Rafi, Nikoobakhsh Mahdi. Evaluation of the safety and efficacy of direct oral anticoagulants compared with vitamin-k antagonists in the treatment of left ventricular thrombosis. A systematic review and meta-analysis. Heart Lung. 2024;67:121-136. doi:10.1016/j.hrtlng.2024.04.019
Abstract
BACKGROUND: Since the introduction of direct oral anticoagulants (DOACs) and their comparison with vitamin K antagonists (VKAs), conflicting results have been reported regarding the optimal treatment for left ventricular thrombosis (LVT). OBJECTIVES: In this meta-analysis, we intend to comprehensively evaluate the safety and efficacy of these treatments. METHODS: All clinical trials and cohorts that compared the efficacy or safety of VKAs with DOACs in the treatment of LVTs were systematically searched until April 15, 2023. RESULTS: The results of 32 studies with a pooled sample size of 4213 patients were extracted for meta-analysis. DOACs, especially rivaroxaban and apixaban, cause faster resolution, lower mortality, and fewer complications (SSE and bleeding events) than VKAs in the management of LVTs. CONCLUSION: Compared with VKAs, DOACs result in significantly faster (only rivaroxaban) and safer resolution of left ventricular thrombosis.
Key Findings
The results of 32 studies with a pooled sample size of 4213 patients were extracted for meta-analysis. DOACs, especially rivaroxaban and apixaban, cause faster resolution, lower mortality, and fewer complications (SSE and bleeding events) than VKAs in the management of LVTs.
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | See abstract |
| Sample Size | 4213 |
| Age Range | See abstract |
| Condition | See abstract |
MeSH Terms
- Humans
- Vitamin K
- Thrombosis
- Heart Ventricles
- Administration, Oral
- Anticoagulants
- Factor Xa Inhibitors
- Rivaroxaban
- Heart Diseases
- Pyrazoles
- Pyridones
Evidence Classification
- Level: Meta Analysis
- Publication Types: Journal Article, Systematic Review, Meta-Analysis
- Vertical: vitamin-k
Provenance
- PMID: 38754272
- DOI: 10.1016/j.hrtlng.2024.04.019
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09